CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Tixel C +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04889950
NCT04889950N/ACompleted

A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel Versus Lipiflow in the Treatment of Meibomian Gland Dysfunction.

Novoxel Ltd.·interventional·Posted May 17, 2021·Updated Nov 15, 2024

In Brief

A clinical study evaluating Tixel C and LipiFlow for Dry Eye Syndromes and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study of the Effectiveness and Safety of the Tixel®, Versus LipiFlow® in the Treatment of Meibomian Gland Dysfunction. Up to 30 patients (60 eyes) to be randomized in up to 2 clinical sites in Israel and/or Europe. study subject will receive three (3) treatments with Tixel in a monthly interval, and a single treatment for the control group. Follow-up will occur 1 month and 3 months following the last treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 17, 2021
Enrollment StartOct 26, 2021
Primary CompletionJan 4, 2023
Study CompletionFeb 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.1 years ago

Interventions

Tixel Cdevice

Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.

LipiFlowdevice

LipiFlow